DexCom, Inc. (DXCM) 47th Annual Raymond James Institutional Investor Conference March 2, 2026 1:05 PM ESTCompany ParticipantsJereme Sylvain - Executive ...
DexCom (NASDAQ: DXCM) has outperformed the market over the past 10 years by 2.92% on an annualized basis producing an average annual return of 16.14%. Currently, DexCom has a market capitalization of ...
Add Yahoo as a preferred source to see more of our stories on Google. Your device's unique device identifier and model number are on the back of your receiver. Some of Dexcom's continuous glucose ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance. DexCom's steep valuation is only justifiable with sustained ...
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported ...
UnitedHealth Group announced plans this morning to distribute a device-driven diabetes management model to 230,000 employer-sponsored members with Type 2 diabetes at no additional cost. The pilot ...
DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...
Dexcom experienced it's largest ever technical glitch over the weekend. The company's technology chief acknowledged that Dexcom needs to do better. Dexcom is analyzing its tech infrastructure and ...
We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results